Richie's Specialty Pharmacy

08/14/2026

Doctors. PAs. NPs. Healthcare providers across Texas.

When you are treating an infection, the opinion is not the endpoint — the science is.

At Richie’s Specialty Pharmacy, we believe strongly in following the available data, reviewing the literature, understanding the organism, evaluating the site of infection, and working collaboratively with healthcare providers to develop thoughtful treatment approaches.

That mindset is a big part of who we are.

When treating infections — FOLLOW THE SCIENCE.

That’s Richie’s.

We continue to build and share clinical resources that healthcare providers can review for themselves:

🔬 www.clinicaleducation.info — explore clinical literature and educational resources

🧪 www.bassagel.com — learn more about BASSAGEL® and its potential role in compounded topical approaches

And if you are a physician, PA, NP, or other healthcare provider anywhere in Texas and would like us to come to your office and talk through the science, the literature, and the approaches we work with every day, we would love the opportunity.

📧 Email Richie at [email protected] to schedule an in-office presentation.

Science. Experience. Results.

That’s the Richie’s difference.

08/14/2026

🧪 Healthcare Provider Request → Formulation Development → Testing → Sharing

Sometimes the most interesting compounding projects start with a simple question from a healthcare provider:

“Could suzetrigine tablets be incorporated into SubMagna® HMW?”

We decided to find out.

Our team developed and tested a compounded formulation using commercially available suzetrigine tablets that were pulverized and incorporated into SubMagna® HMW as a potential sublingual dosage-form approach.

Importantly, this is not a medication currently provided by Richie’s Specialty Pharmacy for prescribing or dispensing to patients. This was a formulation-development project performed in response to healthcare-provider interest.

Why do the work if we are not currently dispensing it?

Because we believe there is tremendous value in testing ideas, generating information, and then sharing what we learn with other healthcare professionals.

The tested formulation has been added to www.rsp-rx.com, where healthcare providers and pharmacies can review it alongside many of the other formulations we have developed and shared.

Suzetrigine is especially interesting because of the enormous need for additional approaches to acute pain management and continued interest in non-opioid pain therapies.

This is what collaboration can look like:

🔹 A healthcare provider asks the question.
🔹 A compounding pharmacy explores the formulation.
🔹 The formulation is tested.
🔹 The information is shared.
🔹 Other healthcare providers can evaluate whether the work may be useful to them.

We do not have to dispense every formulation we develop for the work to have value.

If another pharmacist, physician, PA, NP, researcher, or healthcare organization can take something we learned and build upon it, that is a win.

🌎 Healthcare providers worldwide are welcome to review what we are sharing at www.rsp-rx.com.

Important: This formulation-development work does not establish safety, efficacy, bioequivalence, or clinical effectiveness of a compounded sublingual suzetrigine preparation. The formulation is not currently offered by Richie’s Specialty Pharmacy for patient prescribing or dispensing. Compounded medications are not reviewed by FDA for safety or efficacy.



SubMagna HMW

08/13/2026

What happens when a healthcare provider brings us an idea worth exploring?

Sometimes, we test it.

A healthcare provider request led us to evaluate a compounded combination of Tadalafil 5 mg + NAD+ 75 mg in a single daily preparation. The formulation was compounded, independently analyzed for potency, and the tested sample measured in range.

Importantly, Richie’s Specialty Pharmacy is not currently dispensing this formulation.

This was simply an idea brought forward by healthcare providers that we believed was worth developing, testing, analyzing - and then freely sharing with others who may want to review it.

That is a big part of what we want www.rsp-rx.com to become:

🔹 Healthcare providers bring forward ideas.

🔹 Formulations can be developed and evaluated.

🔹 Testing and analytical information can be generated when appropriate.

🔹 What we learn can be shared so other healthcare professionals and pharmacies can consider it for themselves.

We believe collaboration can move compounding forward.

Whether you are a pharmacist, physician, PA-C, NP, or another healthcare professional, we invite you to review the formulations and information being shared at: www.rsp-rx.com

See something useful? Share it with a colleague.

Have an idea you think deserves to be explored? We would love to hear it.

Compounded medications are not reviewed by FDA for safety or efficacy.

08/12/2026

As reported by CBS News and Fierce Pharma, Eli Lilly has now filed lawsuits tied to the alleged sale of retatrutide products.

For compounding pharmacists who understand the regulatory landscape, this should come as no surprise.

Retatrutide remains investigational, and there is no legal regulatory pathway for compounding this drug for patient use. That is exactly why compliance, sourcing, and patient safety matter so much.

This is an important reminder for pharmacists, prescribers, and industry stakeholders alike: just because there is demand for a drug does not mean there is a lawful path to compound it.

Articles worth reviewing:

CBS News: https://www.cbsnews.com/news/eli-lilly-lawsuits-weight-loss-drug/

Fierce Pharma: https://www.fiercepharma.com/pharma/lilly-takes-6-companies-court-selling-retatrutide-knockoffs

For industry awareness only — not legal advice.

08/12/2026

🩸 A compounded topical approach worth talking about.

We’re excited to highlight our latest PNG featuring Compounded Tranexamic Acid 7.5% in BASSAGEL® — a localized topical option that may be worth considering when a healthcare provider is looking at bleeding situations such as nosebleeds and other accessible areas where direct application and pressure may be helpful.

What makes this approach especially interesting is its simplicity:

✅ Localized application

✅ Potentially cost-effective

✅ Easy to understand and deploy

✅ A practical option for healthcare providers to evaluate

For those exploring compounded approaches to bleeding management, this is another example of how customized preparations can create useful, clinically relevant options.

The formulation and approach are available for review at www.rsp-rx.com.

Just as importantly, we are always glad to share what we’re doing with interested parties worldwide. If you’re a pharmacist, prescriber, clinic, healthcare organization, or collaborator anywhere in the world and would like to discuss the approach, review the formulation, or explore how it may fit your practice, we would love to connect.

We are enthusiastic about helping anyone, anywhere who has a sincere desire to collaborate, learn, and serve patients well.

Bassagel Kingdom Investment Holdings

08/12/2026

Budesonide for nasal health does not have to mean adding another expensive therapy to the medicine cabinet.

For some appropriately insured patients, Budesonide from Richie’s Specialty Pharmacy may be available for $0 per month. For others, it can still be a very cost-effective prescription option depending on their insurance coverage.

That matters when you consider how quickly multiple OTC products can add up. Patients dealing with ongoing nasal symptoms may find themselves buying several products month after month - nasal sprays, antihistamines, decongestants, mucus-relief products and more.

A prescriber-directed Budesonide nasal irrigation approach may help simplify the treatment plan and potentially reduce the need for multiple OTC products, depending on the patient’s individual needs.

At Richie’s Specialty Pharmacy, we focus on making nasal health treatment:

· Affordable - including the possibility of a $0 copay for many patients

· Simple - one coordinated prescription approach instead of a shelf full of products

· Convenient - delivered directly to patients across Texas

· Flexible - with additional compounded nasal medications available when clinically appropriate

· Provider-driven - treatment remains directed by the patient’s healthcare provider

If you prescribe Budesonide, or you have patients routinely spending money on multiple OTC nasal products, it may be worth comparing the options.

Better nasal health does not necessarily have to cost more.

Visit Richies.com or reach out to Richie’s Specialty Pharmacy to learn more about prescription Budesonide options and potential insurance coverage.

Copays and coverage vary by insurance plan. Medication changes should always be directed by the patient’s healthcare provider.

Compounded medications are not reviewed by FDA for safety or efficacy.

08/11/2026

Peptides: If the Door Opens, It’s Game On

Take a look at the Endpoints News article linked below regarding Hims & Hers and its readiness to move quickly if FDA regulatory changes open the door for six wellness peptides.

https://endpoints.news/hims-able-to-move-extremely-quickly-if-fda-greenlights-six-wellness-peptides-ceo-says/?u=74218e45-ef29-4c0b-a655-a8ff1b0b4798&s=email&c=107e23d7-6f394367-0c2434c2&utm_medium=email&utm_campaign=Hims%20is%20ready%20for%20a%20peptide%20world%20Insider&utm_content=Hims%20is%20ready%20for%20a%20peptide%20world%20Insider+CID_5f5809e9f744a8499522f06498ac2785&utm_source=ENDPOINTS%20emails&utm_term=Hims%20able%20to%20move%20extremely%20quickly%20if%20FDA%20greenlights%20six%20wellness%20peptides%20CEO%20says

The six peptides receiving the recent favorable advisory committee recommendations are:

• BPC-157
• KPV
• TB-500
• MOTS-c
• Epitalon
• Semax

Hims is essentially saying: if the regulatory environment changes, they are ready to move.

It would be “game on” at Richie’s as well.

If these peptides ultimately become permissible for 503A compounding, we want to be positioned to immediately evaluate all six for compounded sublingual delivery using SubMagna® HMW.

That could create an entirely different conversation around peptide therapy.

Instead of assuming every peptide needs to be delivered by injection, our focus would be on determining which of these molecules can be appropriately formulated, stabilized and delivered through a patient-friendly compounded sublingual dosage form.

No needles. Potentially simpler administration. Prescriber-directed dosing. A dosage form that may be much easier to incorporate into a patient’s routine.

There is still regulatory work to be completed. The advisory committee recommendation does not mean these peptides are FDA-approved or that pharmacies can begin compounding them today.

But if the door opens, Richie’s intends to be ready.

BPC-157. KPV. TB-500. MOTS-c. Epitalon. Semax.

If the regulatory changes occur, our objective is simple:

Evaluate them. Formulate them. Validate what can be validated. Determine where SubMagna® HMW can provide a practical sublingual alternative.

And, of course, there is one more part of the plan:

As the formulas are finalized and validated, they’ll start finding their way to www.rsp-rx.com - because what good is figuring something out if we can’t share it with other healthcare providers and pharmacies?

The peptide landscape could change significantly.

If it does: game on. And keep an eye on www.rsp-rx.com.

As always, compounded medications are not reviewed by FDA for safety or efficacy.

Hims CEO Andrew Dudum says company is testing BPC-157 and other peptides, planning to offer Sermorelin, Glutathione & NAD+ by 2026. Q2 revenue hit $753M.

08/11/2026

Low Dose Naltrexone (LDN) in SubMagna® HMW: A Simple Compounding Approach Worth Reviewing

A growing number of healthcare providers are familiar with low dose naltrexone (LDN) and the wide range of prescriber-directed conversations surrounding its potential use.

From autoimmune-related discussions to neuropathic pain, fibromyalgia, neuroinflammation, GI-related symptoms, and other individualized patient needs, LDN continues to be a topic of interest across multiple areas of practice.

Compounded LDN in SubMagna® HMW offers a simple approach to evaluate:

• Simple: A compounded sublingual liquid dosage form that can be prepared in a straightforward, practical format.
• Flexible: A 9 mg/1 mL concentration allows for flexible dosing and titration based on prescriber direction and patient need.
• Cost-conscious: A customizable compounded option may help pharmacies and providers explore practical approaches to cost containment and patient access.
• Widely shareable: The formulation is available for healthcare providers worldwide to review and, if appropriate, deploy through the compounding pharmacy of their choice.

That last point matters.

The goal is not to keep useful compounding approaches locked inside one pharmacy.

At www.rsp-rx.com, pharmacists, physicians, NPs, PAs, and other healthcare professionals can review formulations and consider whether they may be useful in their own practices and patient care settings.

You do not have to use one specific pharmacy to benefit from the work.

If your preferred compounding pharmacy can prepare the formulation appropriately, the information is there for review and consideration.

Better access to practical formulations.

More flexibility for providers.
More options for patients.
More freedom for pharmacies to evaluate and deploy useful compounded approaches.

That is exactly the spirit behind RSP-RX.com.

Explore this and other shared formulations at www.rsp-rx.com.
Compounded medications require a valid prescription and are not reviewed by FDA for safety or efficacy.

08/10/2026

BETAHISTINE in SubMagna® HMW: A Simple Compounding Approach for a Significant Patient Need

Dizziness, balance disorders, vertigo, Ménière’s disease and other vestibular complaints affect a significant number of patients – and for some, available treatment options may leave room for additional prescriber-directed approaches.

Compounded BETAHISTINE in SubMagna® HMW offers healthcare providers a relatively simple option to evaluate:

Simple: A compounded sublingual liquid with customizable dosing and titration.

Patient-focused: May be considered in conversations involving Ménière’s disease, vestibular or peripheral vertigo, dizziness/balance complaints and other vestibular conditions.

Cost-conscious: A straightforward compounded formulation can give pharmacies another approach to evaluate when considering patient affordability and overall cost containment.

Not tied to one pharmacy: The goal is to make the formulation available for healthcare providers and pharmacists to review, discuss and potentially deploy through the pharmacy of their choice.

That last point is important.

At www.rsp-rx.com, we are making formulations and related information available to interested healthcare providers worldwide. Pharmacists, physicians, PAs, NPs and other healthcare professionals are welcome to review the approach.

You do not have to send a prescription to Richie’s to benefit from the work. If your preferred compounding pharmacy can appropriately prepare the formulation, we want them to have the opportunity to review it too.

Better access to information.

Simpler compounding approaches.

More pharmacy choice.

Greater attention to cost containment.

That is exactly what RSP-RX.com is intended to support.

Explore the formulation and other shared compounding approaches at www.rsp-rx.com.

Compounded medications require a valid prescription and are not reviewed by FDA for safety or efficacy.

SubMagna HMW Kingdom Investment Holdings

08/10/2026

Compounded Triple-Anesthetic Topical Gel

Benzocaine 7% + Lidocaine 7% + Tetracaine 7% in BASSAGEL®

This compounded topical local anesthetic option may be useful in select provider-directed settings such as tattoos, laser / tattoo removal, fillers, minor skin procedures, IV / needle-stick prep, and other topical anesthetic needs.

One of the things we are most excited about is that this formula is available for review at www.rsp-rx.com and can be shared with interested parties worldwide. We believe independent pharmacies and healthcare providers benefit when practical, clinically relevant compounded options are easier to access and evaluate.

If you are a pharmacy, prescriber, or healthcare professional anywhere in the world, we welcome you to review the formula and consider whether it may be helpful in your practice.

And if you are in Texas and would like Richie’s Specialty Pharmacy to help support your patients with compounded topical preparations, reach out to us - we’d be glad to help.

Compounded medications are not reviewed by FDA for safety or efficacy. Use only as directed by the prescriber.



Bassagel Kingdom Investment Holdings